Abstract
Blastocystis is one of the most common parasites found in the gut of humans and other hosts. It has a wide genetic diversity distributed around the world, predominating subtypes 1, 2 and 3 in South America countries. Nonspecific and inconsistent symptoms associated with this parasite made it controversial. The aim of this study was to estimate the prevalence of subtypes and determinate the epidemiological conditions associated with them. A total of 116 Blastocystis positive stool samples were processed by conventional PCR with Blastocystis-specific primers for subtypes 1 to 3. We identified subtype 1 (10.3%), subtype 2 (7.6%), subtype 3 (25.0%) and mixed infections (8.6%). We did not identify these Blastocystis subtypes in 48.7% of stool samples, assuming the presence of other subtypes in the zone. Any association was found between gastrointestinal symptoms and single subtype infections neither with mixed subtypes coinfections. However, our results suggest an association of Blastocystis subtype 2 and Irritable Bowel Syndrome (IBS, p=0.039). Besides, there was not an association between Blastocystis subtypes 1, 2 and 3 nor-mixed infections with epidemiological variables such as gender, age, presence of animals or vectors, places of food consumption, type of water consumption and water supply.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Universidad Nacional de San Agustín (UNSA), project “Morphological, Molecular and Clinical Diagnosis of Blastocystis as an emerging disease in humans and its association with the treatment and keeping of animals”. Proyectos de Investigación Aplicada Inicial-2017 Contrato IAI 002-2018-UNSA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol of this study was reviewed and approved by the Institutional Review Boards of the Universidad Peruana Cayetano Heredia, reference number 18006.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.